Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE

Status Not yet recruiting

Clinical Trial Summary

Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies.The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis

Clinical Trial Description

Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies . Lupus nephritis (LN) is the most common and serious complication in SLE patients characterized by proteinuria, hematuria, drop glomerular filtration rate, or renal dysfunction . It is known that B lymphocytes are involved in the pathogenesis of systemic lupus erythematosus in autoantibody-dependent mechanisms . The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), is a CXC subtype member of the chemokine superfamily. The receptor of CXCL13 is CXCR5, which is normally expressed on mature B cells and follicular T helper cells (Tfh). It has been demonstrated that CXCL13 is sufficient to induce secondary lymphoid tissues in peripheral organs. It is well known that different chemokines are involved in the pathogenesis of LN by orchestrating proinflammatory microenvironments, recruiting immune cell subsets into the kidney and by inducing local activation of immune effector cells . Local B-cell infiltration and related abnormal expression of ectopic lymphoid tissue (ELT) in the renal tissues of LN mice models was related to the severity of renal impairment .

Of interest, in regions of B cell infiltration a higher expression level of CXCL13 was found. Most B cells in this region expressed the corresponding receptor CXCR5, also supporting the hypothesis that CXCL13 induces B cell infiltration into the kidneys via its receptor CXCR5 .

In one study on 91Caucasian patients, CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis. It was found that serum CXCL13 levels correlated well with SLEDAI and median CXCL13 concentrations were higher in patients with renal involvement . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03752983
Study type	Observational
Source	Assiut University
Contact	Mariam Mohamed, Master
Phone	+2001004519831
Email	mariamnassar174@yahoo.com
Status	Not yet recruiting
Phase
Start date	March 1, 2019
Completion date	December 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03749044` - ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies	N/A
Completed	`NCT03218033` - Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus	N/A
Recruiting	`NCT03819777` - Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Recruiting	`NCT04894253` - Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
Not yet recruiting	`NCT03164720` - SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
Completed	`NCT03762824` - Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease	Phase 4
Not yet recruiting	`NCT06435468` - Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases	N/A
Terminated	`NCT01738360` - Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)	Phase 2
Completed	`NCT03430388` - Yellow Fever Vaccine in Patients With Rheumatic Diseases	N/A
Completed	`NCT04108611` - Immune Adsorption Role in Treatment of Resistant Lupus	N/A
Not yet recruiting	`NCT04256577` - Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
Completed	`NCT03540823` - Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.